Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase.
FASN
LINC02570
SREBP1
miR-4649-3p
nasopharyngeal carcinoma (NPC)
progression
Journal
Bioengineered
ISSN: 2165-5987
Titre abrégé: Bioengineered
Pays: United States
ID NLM: 101581063
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
entrez:
21
9
2021
pubmed:
22
9
2021
medline:
29
12
2021
Statut:
ppublish
Résumé
Our previous studies have elucidated a possible connection between long intergenic non-protein coding RNA 2570 (LINC02570) and nasopharyngeal carcinoma (NPC). However, the precise mechanism by which LINC02570 promotes NPC remains unknown. We used quantitative polymerase chain reaction (qPCR) to detect LINC02570 expression in nasopharyngeal cell lines, NPC tissues, and chronic rhinitis tissues. Subcellular LINC02570 localization was confirmed by fluorescence
Identifiants
pubmed: 34546840
doi: 10.1080/21655979.2021.1979317
pmc: PMC8806647
doi:
Substances chimiques
MicroRNAs
0
RNA, Long Noncoding
0
SREBF1 protein, human
0
Sterol Regulatory Element Binding Protein 1
0
FASN protein, human
EC 2.3.1.85
Fatty Acid Synthase, Type I
EC 2.3.1.85
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7119-7130Références
Medicine (Baltimore). 2019 Nov;98(48):e17997
pubmed: 31770211
Cancer Cell Int. 2020 Apr 28;20:138
pubmed: 32368184
Int J Cancer. 2020 Apr 15;146(8):2336-2347
pubmed: 31469434
Environ Int. 2021 Jun;151:106455
pubmed: 33652252
Oncol Lett. 2017 Sep;14(3):2669-2676
pubmed: 28927029
Philos Trans R Soc Lond B Biol Sci. 2017 Oct 19;372(1732):
pubmed: 28893937
Int J Mol Sci. 2016 Dec 09;17(12):
pubmed: 27941681
Bioengineered. 2021 Dec;12(1):2175-2186
pubmed: 34057029
Int J Mol Med. 2015 Aug;36(2):559-64
pubmed: 26081980
J Pathol. 2018 Oct;246(2):180-190
pubmed: 29968360
Curr Pharm Des. 2014;20(15):2619-26
pubmed: 23859617
Eur Rev Med Pharmacol Sci. 2020 Jan;24(1):174-180
pubmed: 31957830
Tumori. 2018 Jan-Feb;104(1):37-42
pubmed: 29699474
Biomed Res Int. 2019 Jun 11;2019:7246491
pubmed: 31309112
Cancer Lett. 2020 May 28;478:122-132
pubmed: 32165272
Lancet. 2019 Jul 6;394(10192):64-80
pubmed: 31178151
Oncotarget. 2016 Sep 20;7(38):61741-61754
pubmed: 27557514
Cell. 2015 Feb 12;160(4):595-606
pubmed: 25640239
Radiat Oncol. 2019 Jan 17;14(1):9
pubmed: 30654815
PLoS One. 2020 Apr 9;15(4):e0230524
pubmed: 32271791
Onco Targets Ther. 2020 May 20;13:4397-4409
pubmed: 32606725
Eur Rev Med Pharmacol Sci. 2020 Mar;24(6):3077-3084
pubmed: 32271425
N Engl J Med. 2017 Aug 10;377(6):513-522
pubmed: 28792880
Front Oncol. 2021 Jan 25;10:632813
pubmed: 33569351
Gene. 2020 Feb 15;727:144243
pubmed: 31743768
Bioengineered. 2021 Dec;12(1):2228-2237
pubmed: 34057022
BMC Cancer. 2020 May 5;20(1):376
pubmed: 32370736
Proc Natl Acad Sci U S A. 2018 May 29;115(22):E5115-E5124
pubmed: 29760067
Cell Cycle. 2020 Jun;19(11):1352-1362
pubmed: 32264733
Eur Rev Med Pharmacol Sci. 2020 Apr;24(7):3724-3733
pubmed: 32329849
Asian Pac J Cancer Prev. 2013;14(11):6315-9
pubmed: 24377524
Onco Targets Ther. 2017 May 30;10:2769-2778
pubmed: 28615956
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Cell. 2018 Jan 25;172(3):393-407
pubmed: 29373828